Chemistry: analytical and immunological testing – For preexisting immune complex or auto-immune disease – Immune complex
Reexamination Certificate
2006-10-17
2006-10-17
Campell, Bruce R. (Department: 1648)
Chemistry: analytical and immunological testing
For preexisting immune complex or auto-immune disease
Immune complex
Reexamination Certificate
active
07122380
ABSTRACT:
A pharmaceutical composition suitable for administration to human beings in the prevention or treatment of immunologic disorders includes:an immune complex of an antigen and a purified antibody specific thereto, the antigen being selected from a group consisting of antigens that cause pathogenic immunologic reactions in autoimmune disease and graft rejections, and the antigen and antibody being present in a ratio whereby the antibody blocks essentially all binding sites of the antigen; and a pharmacologically acceptable carrier or diluent.The invention also provides a method of administering the composition for treatment of autoimmune disease and treatment or prevention of graft rejections.
REFERENCES:
patent: 4140679 (1979-02-01), Malley
patent: 4234569 (1980-11-01), Marsh
patent: 4344938 (1982-08-01), Sedlacek et al.
patent: 4521405 (1985-06-01), McMichael
patent: 4545986 (1985-10-01), Malley
patent: 4564600 (1986-01-01), Ali et al.
patent: 4681760 (1987-07-01), Fathman et al.
patent: 4702907 (1987-10-01), Becker et al.
patent: 4714759 (1987-12-01), Whitaker, Jr.
patent: 0217577 (1987-04-01), None
patent: 0240344 (1987-10-01), None
patent: 0245078 (1987-11-01), None
Schwartz, R.S., “Autoimmunity and Autoimmune Diseases” inFundamental Immunology, 3rd Ed., Paul, W.E., Ed., Raven Press, New York, pp. 1069-1074, 1993.
Brostoff et al.,Clinical Immunology, Gower Medical Publishing, New York, pp. 6.1-6.14, 1991.
Putterman et al, “Murine Models of Spontaneous Sytomic Lupus Erythematasus,” inAutoimmune Disease Models: A Guidebook, Academic Press, San Diego, pp. 217-243, 1994.
Barkas et al., J. Clin. Lab Immunol. 7 (1982) p. 223.
Borel et al., J. Clin. Investigation 82 (1988) p. 1901.
Borel et al., Ann. N.Y. Acad. Sci. 476 (1986) p. 296.
Borel et al., J. of Immunological Methods 126 (1990) p. 159.
Caulfield et al., J. Immunology 138 (1987) p. 3680.
Farkas et al. Immunology 45 (1982) p. 483.
Klaus, Nature 272 (1978) p. 265.
Klaus, Immunology 37 (1979) p. 345.
Klaus, Nature 278 (1979) p. 354.
G. G. B. Klaus, “Antigen-antibody Complexes Elicit Anti-Idiotypic Antibodies to Self-Idiotopes,”Nature, vol. 272, pp. 265-266, Mar. 16, 1978.
A. I. Farkas, et al, “Immunogenicity of Antigen Complex With Antibody,”Immunology, vol. 45, pp. 483-492, 1982.
Klaus, “Cooperation Between Antigen-Reactive T Cells and Anti-Idiotypic B Cells in the Anti-Idiotypic Response . . . ” 278 Nature 354 (Mar. 22, 1979).
Roitt, I. et al.,Immunology, C.V. Mosby Co., St. Louis (1985) pp. 21.1-21.10.
Barkas, T. et al., “Preliminary Communication Experimental Myasthenia Gravis is Inhibited by Receptor-Antireceptor Complexes”,J. Clin. Lab. Immunol., vol. 7 (1982), pp. 223-227.
Borel, H. et al., “A Possible New Therapy of Systemic Lupus Erythematosus (SLE)a”,Ann. N.Y. Acad. Sci., vol. 476 (1986) pp. 296-305.
Caulfield, M.J. et al., “Immunoregulation by Antigen/Antibody Complexes I. Specific Immunosuppression Induced in Vivo with Immune Complexes Formed in Antibody Excess”,Journal of Immunology, vol. 138 (1987), pp. 3689-3683.
Borel, Y. et al., “Oligonucleotide Linked to Human Gammaglobulin Specifically Diminishes Anti-DNA Antibody Formation in Cultured Lymphoid Cells from Patients with Systemic Lupus Erythematosus”,J. Clin Invest., vol. 82 (1988), pp. 1901-1907.
Borel, H. et al., “A novel technique to link either proteins or peptides to gammaglobulin to construct tolerogens”,Journal of Immunological Methods, vol. 126 (1990) pp. 159-168.
Caulfield, M., “Idiotype-Restricted Antibody Response to Specific Immune Complexes”,Cellular Immunology, vol. 90 (1985), pp. 451-437.
Caulfield, M. et al., “The Antibody Response to Specific Immune Complexes is Under Genetic Control and Correlates with the Expression of a Recurrent Idiotype”,J. Exp. Med., vol. 163 (1986), pp. 75-86.
Filion, L.G. et al., “Suppression of the IgE Antibody Response to Ovalbumin in Mice with a Conjugate of Ovalbumin and Isologous γ-Globulins”,Cellular Immunology, vol. 54 (1980), pp. 115-128.
Lee, W.Y. et al. “Suppression of Reaginic Antibody Formation I. Introduction of Hapten-Specific Tolerance”,The Journal of Immunology, vol. 114, No. 2, Part 2 (1975), pp. 829-836.
Lee, W.Y. et al., “Tolerization of Bε Cells by Conjugates of Haptens and Isologous γ-Globulins”,Cellular Immunology, vol. 58, (1981), pp. 385-397.
Seropian, E. et al., “‘Alergim’—Blocking Antibody IgG Specific in Intraseasonal Treatments of Pollenosis: Clinical Results”,Imunolgie XIII, Academia De Stiinte Medicale Comisia Nationala De Imunologie Subcomisia Tirgu Mures.
Seropian, E. et al., “‘ALERGIM’, A Specific Immune Complex for the Intraseasonal Treatment of Pollinosis. A Clinical Trial”,Abstracts Interlaken 1984—6th European Immunology Meeting, (1984), p. 325.
Uhr, J.W. et al., “Regulatory Effect of Antibody on the Immune Response”,Advances in Immunologyvol. 8, (1968) pp. 81-127.
Andrew F. Geczy, et al, “Suppression of Reaginic Antibody Formation in Guinea Pigs by Anti-idiotypic Antibodies,”J. Allergy Clin Immunol, vol. 62(5): 261-270, 1978.
Kurt Blaser, et al, “Suppression of Phosphorylcholine-Specific IgE Antibody Formation in BALB/c Mice by Isologous Anti-T 15 Antiserum,” Eur. J. Immunol. 1979.9:1017-1020.
Kurt Blaser, et al, “Suppression of the Benzylpenicilloyl-(BPO) Specific IgE Formation With Isologous Anti-Idiotypic Anti-bodies in BALB/c Mice,”The Journal of Immunology, vol. 125, No. 1, pp. 24-30, Jul. 1980.
K. Blaser, et al, “Investigation of a Syngeneic Murine Model for the Study of IgE Antibody Regulation With Isologous, Antiidiotypic Antibodies,”Int. Archs Allergy Appl. Immun. 64: 42-50 (1981).
Raif S. Geha, M.D., “Current Concepts in Immunology,”The New England Journal of Medicine, vol. 305, No. 1, pp. 25-28, Jul. 2, 1981.
A. I. Farkas, et al, “Immunogenicity of Antigen Complex With Antibody,”Immunology, vol. 45, pp. 483-492, 1982.
Raif S. Geha & Marc Comunale, “Regulation of Immunoglobulin E Antibody Synthesis in Man by Antiidiotypic Antibodies,”J. Clin. Invest., vol. 71, pp. 46-54, Jan. 1983.
Paul D. Buisseret, “Allergy,”Scientific American, pp. 82-91, Aug. 1982.
Howard J. Sanders, “Allergy, A Protective Mechanism Out of Control,”Chemical&Engineering News, vol. 48, pp. 84-135, May 11, 1970.
“Primer on Allergic and Immunologic Diseases,”Journal of the American Medical Association, vol. 248, No. 20, Nov. 26, 1982.
Arend et al, “In Vitro Adherence of Soluble Immune Complexes to Macrophages”, 136 J. Exp. Med. 514 (1972).
Klaus, “Generation of Memory Cells, III. Antibody Class Requirements for the Generation of B-Memory Cells by Antigen-Antibody . . . ” 37 Immunology 345 (1979.
Caulfield et al, “Induction of Idiotype-Specific Suppressor T Cell with Antigen/Antibody Complexes”, 157 J. Exp. Med. 1713 (1983).
Blaser et al, “Immune Networks in Immediate Type Allergic Diseases”, 418 Ann. NY Acad. Sci . 330 (1983).
Blaser et al, “Regulation of the IgE Antibody Response by Idiotype-Anti-Idiotype Network”, 32 Prog. Allergy 203 (1982).
Blaser et al, “Regulatory Effects of Isoloqous Anti-idiotypic Antibodies on the Formation of . . . ”, 14 Eur. J. Immunol. 93-98 (1984) 50 Fed. Reg. 3082 (Jan. 23, 1985).
Glover, D.M.,Gene Cloning: The Mechanics of DNA Manipulation, pp. 102-104, Chapman and Hall, London (1984).
Lee, W.Y. et al., “Suppression of Reaginic Antibody Formation IV. Suppression of Reaginic Antibodies to Penicillin in the Mouse”,The Journal of Immunology, vol. 117, No. 3 (1976) pp. 927-934.
Old, R.W. et al., “Principles of Gene Manipulation An Introduction to Genetic Engineering”,Studies in Microbiology, vol. 2 (1981) pp. 104-
Jacquemin Marc
Lebecque Serge
Lebrun Philippe
Masson Piere
St. Remy Jean-Marie
International Institute of Cellular and Molecular Pathology
McCann Clifton E.
Venable LLP
LandOfFree
Pharmaceutical compositions containing antigen-antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions containing antigen-antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions containing antigen-antibody... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3652650